Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

PHASE4RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

March 30, 2025

Conditions
Acute Decompensated Heart FailureVolume OverloadEdema
Interventions
DRUG

Acetazolamide

"Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily."

DRUG

Metolazone

"Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily."

DRUG

IV Loop Diuretics

IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.

Trial Locations (1)

3755204

RECRUITING

National Heart Institute, Giza

All Listed Sponsors
collaborator

National Heart Institute, Egypt

OTHER_GOV

lead

Cairo University

OTHER